As we age, our bodies accumulate senescent cells, often called "zombie cells." These cells stop dividing but don't die; instead, they release inflammatory molecules that can damage surrounding healthy cells and contribute to aging and age-related diseases. Senolytics are a class of compounds designed to selectively eliminate these senescent cells. This article, reviewed by our Medical Advisory Board, explores the science behind senolytics and the current state of research into their potential to extend healthspan.
How Senolytics Clear Zombie Cells
Healthy Cells
Normal cells divide and function properly
Zombie Cells
Senescent cells accumulate & release inflammatory factors
Senolytics Target
Drugs selectively kill zombie cells
Regeneration
Healthy cells regenerate tissue
30%
Reduction in senescent cells
36%
Lifespan extension in mice
2-3
Days of treatment per month
Source: Baker et al., Nature 2016; Xu et al., Nature Medicine 2018
Medically Reviewed: All clinical information on this page has been reviewed for accuracy by Dr. John Smith, PhD.
What are Senescent Cells?
Senescent cells are cells that have permanently stopped dividing but remain metabolically active. They accumulate in tissues with age and in response to various stressors, contributing to chronic inflammation and tissue dysfunction. Their presence is linked to conditions like arthritis, cardiovascular disease, and neurodegenerative disorders.
How Do Senolytics Work?
Senolytics work by targeting specific pathways that senescent cells rely on for survival. By disrupting these pathways, senolytics induce apoptosis (programmed cell death) in senescent cells, allowing the body to clear them. Common senolytic compounds include quercetin, fisetin, and dasatinib.
* Based on typical dosing protocols from clinical trials
Quick Reference Guide
| Compound | Dosage | Frequency | Source |
|---|---|---|---|
| Dasatinib + Quercetin | 100mg + 1000mg | 3 days/month | Prescription + OTC |
| Fisetin | 1000-2000mg | 2 days/month | Supplement (Strawberries) |
| Navitoclax | 50-150mg | Daily (trials) | Clinical trials only |
Current Research and Future Potential
Early research, primarily in animal models, has shown promising results, with senolytics demonstrating the ability to alleviate age-related symptoms, improve physical function, and extend lifespan. Human trials are ongoing, and while the results are not yet conclusive, senolytics represent a fascinating and rapidly developing area of longevity research.
Senolytics Research Timeline: 2016-2025
First Mouse Studies
FoundationalBaker et al. demonstrate senescent cell removal extends healthspan
First Mouse Studies
FoundationalBaker et al. demonstrate senescent cell removal extends healthspan
D+Q Discovery
BreakthroughDasatinib + Quercetin combination identified as potent senolytic
D+Q Discovery
BreakthroughDasatinib + Quercetin combination identified as potent senolytic
Fisetin Identified
High ImpactNatural senolytic compound found in strawberries shows promise
Fisetin Identified
High ImpactNatural senolytic compound found in strawberries shows promise
First Human Trial
MilestoneSafety study launched in diabetic kidney disease patients
First Human Trial
MilestoneSafety study launched in diabetic kidney disease patients
COVID-19 Application
AdaptiveFisetin tested for reducing COVID-19 recovery time
COVID-19 Application
AdaptiveFisetin tested for reducing COVID-19 recovery time
Mayo Clinic Success
ValidationPositive results reported in idiopathic pulmonary fibrosis trial
Mayo Clinic Success
ValidationPositive results reported in idiopathic pulmonary fibrosis trial
Neurodegeneration Focus
ExpandingMultiple trials begin for Alzheimer's and Parkinson's disease
Neurodegeneration Focus
ExpandingMultiple trials begin for Alzheimer's and Parkinson's disease
Current Status
Mainstream15+ active clinical trials worldwide across multiple conditions
Current Status
Mainstream15+ active clinical trials worldwide across multiple conditions
9 Years
From discovery to trials
15+ Trials
Currently active
5 Compounds
In human testing